{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:12:05Z","timestamp":1771953125388,"version":"3.50.1"},"reference-count":48,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Comprehensive detection of copy number aberrations (CNAs) is critical for precise prognostic risk stratification in multiple myeloma (MM), yet conventional cytogenetic methods remain limited. We developed LeukoPrint, a shallow whole-genome sequencing (sWGS) assay for genome-wide CNA profiling. Using this platform, we analyzed CNA profiles of 423 patients with MM across 3 hospitals and compared LeukoPrint with karyotyping and fluorescence in situ hybridization (FISH) to evaluate its diagnostic performance and clinical utility in prognostic assessment. Compared with karyotyping, LeukoPrint demonstrated a significantly higher abnormality detection rate (75.2% vs 11.2%) and identified CNAs in 73.3% of karyotyping-negative cases. Concordance with FISH for key prognostic CNAs (amp(1q), del(1p), del(13q), del(17p)) was 94.0%. Based on these findings, we propose replacing karyotyping with LeukoPrint combined with FISH for routine diagnostics. Integrating LeukoPrint with FISH results into the Mayo Stratification for Myeloma and Risk-Adapted Therapy risk model reclassified 11.5% of standard-risk patients as high-risk, identifying candidates for intensified therapy. Furthermore, LeukoPrint genome-wide profiling revealed distinct CNA patterns between hyperdiploid and nonhyperdiploid MM, informing biological heterogeneity. LeukoPrint significantly outperforms conventional karyotyping and closely matches FISH for critical CNA markers, offering an alternative for cytogenetic profiling and prognostic risk stratification in MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018133","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T18:00:55Z","timestamp":1765562455000},"page":"1312-1323","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing"],"prefix":"10.1182","volume":"10","author":[{"given":"Baijun","family":"Fang","sequence":"first","affiliation":[{"name":"1Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zunmin","family":"Zhu","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Henan Provincial People\u2019s Hospital, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7108-2639","authenticated-orcid":false,"given":"Yinyin","family":"Chang","sequence":"additional","affiliation":[{"name":"3Clinical Laboratories, Shenyou Bio, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangxiang","family":"He","sequence":"additional","affiliation":[{"name":"3Clinical Laboratories, Shenyou Bio, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0416-526X","authenticated-orcid":false,"given":"Shiyong","family":"Li","sequence":"additional","affiliation":[{"name":"4Research & Development, SeekIn Inc, Shenzhen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manqian","family":"Li","sequence":"additional","affiliation":[{"name":"3Clinical Laboratories, Shenyou Bio, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susu","family":"Yan","sequence":"additional","affiliation":[{"name":"3Clinical Laboratories, Shenyou Bio, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4096-1909","authenticated-orcid":false,"given":"Dandan","family":"Zhu","sequence":"additional","affiliation":[{"name":"3Clinical Laboratories, Shenyou Bio, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenling","family":"Li","sequence":"additional","affiliation":[{"name":"5Department of Hematology, China-Japan Friendship Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8570-8571","authenticated-orcid":false,"given":"Mao","family":"Mao","sequence":"additional","affiliation":[{"name":"6Research & Development, SeekIn Inc, San Diego, CA"},{"name":"7Yonsei Song-Dang Institute for Cancer Research, Yonsei University, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"7377","key":"2026022411390278000_bib1","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1038\/480S33a","article-title":"Multiple myeloma","volume":"480","author":"Brody","year":"2011","journal-title":"Nature"},{"issue":"6","key":"2026022411390278000_bib2","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-10-1843","article-title":"Genomics in multiple myeloma","volume":"17","author":"Munshi","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2026022411390278000_bib3","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","article-title":"Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups","volume":"32","author":"Bolli","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"2026022411390278000_bib4","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"4","key":"2026022411390278000_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41408-019-0199-3","article-title":"Deciphering the chronology of copy number alterations in multiple myeloma","volume":"9","author":"Aktas Samur","year":"2019","journal-title":"Blood Cancer J"},{"issue":"12","key":"2026022411390278000_bib6","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2014-10-567370","article-title":"Genetics of multiple myeloma: another heterogeneity level?","volume":"125","author":"Corre","year":"2015","journal-title":"Blood"},{"issue":"15","key":"2026022411390278000_bib7","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"26","key":"2026022411390278000_bib8","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"29","key":"2026022411390278000_bib9","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY Project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026022411390278000_bib10","unstructured":"Mayo Stratification for\n              \n            \n          . Myeloma and Risk-Adapted Therapy (mSMART) 3.0, Mayo Clinic. https:\/\/globalmmacademy.com\/wp-content\/uploads\/2021\/03\/RiskStrat3.0rev_svr_Mayo-clinic.pdf?utm_source=chatgpt.com&__cf_chl_tk=x4zxvyXbIWY0483L.HrtafV8kGzkyDF6m7mMUeSwquU-1759237772-1.0.1.1-IXSiTocZ8zl9gaSVsDbwYPSDjS.ODGQIwVRG3MnbVuI."},{"key":"2026022411390278000_bib11","unstructured":"Mayo Stratification for\n              \n            \n          . Myeloma and Risk-Adapted Therapy (mSMART) 4.0. Mayo Clinic. https:\/\/static1.squarespace.com\/static\/5b44f08ac258b493a25098a3\/t\/6723e0f5d05ee34b1639f846\/1730404597922\/mSMART%2B4.0%2B%2BRisk%2BStrat%2BOct%2B2024rev.pdf?utm_source=chatgpt.com."},{"issue":"3","key":"2026022411390278000_bib12","doi-asserted-by":"crossref","first-page":"101196","DOI":"10.1016\/j.beha.2020.101196","article-title":"Cytogenetics in the genomic era","volume":"33","author":"Granada","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"15","key":"2026022411390278000_bib13","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood.2021014309","article-title":"Guiding the global evolution of cytogenetic testing for hematologic malignancies","volume":"139","author":"Akkari","year":"2022","journal-title":"Blood"},{"key":"2026022411390278000_bib14","doi-asserted-by":"crossref","first-page":"101168","DOI":"10.1016\/j.blre.2024.101168","article-title":"Chromosomal defects in multiple myeloma","volume":"64","author":"Clarke","year":"2024","journal-title":"Blood Rev"},{"key":"2026022411390278000_bib15","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"issue":"1","key":"2026022411390278000_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"issue":"10","key":"2026022411390278000_bib17","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1080\/10428194.2022.2080821","article-title":"Whole-genome sequencing as an alternative to analyze copy number abnormalities in acute myeloid leukemia and myelodysplastic syndrome","volume":"63","author":"Lyu","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2026022411390278000_bib18","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/gcc.23183","article-title":"Shallow whole-genome sequencing of bone marrow aspirates in myelodysplastic neoplasms: a retrospective comparison with cytogenetics","volume":"62","author":"Rengifo","year":"2023","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"2026022411390278000_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/cge.13561","article-title":"Low-depth sequencing for copy number abnormalities in multiple myeloma supersedes fluorescent in situ hybridization in scope and resolution","volume":"96","author":"Elnenaei","year":"2019","journal-title":"Clin Genet"},{"issue":"8","key":"2026022411390278000_bib20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/gcc.22848","article-title":"Ultra-low depth sequencing of plasma cell DNA for the detection of copy number aberrations in multiple myeloma","volume":"59","author":"Buedts","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"2026022411390278000_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-0716-3946-7_7","article-title":"Chromosome bandings and recognition","volume":"2825","author":"Wan","year":"2024","journal-title":"Methods Mol Biol"},{"issue":"suppl 1","key":"2026022411390278000_bib22","first-page":"1","article-title":"ISCN 2024 - an international system for human cytogenomic nomenclature (2024)","volume":"164","year":"2024","journal-title":"Cytogenet Genome Res"},{"issue":"4","key":"2026022411390278000_bib23","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol"},{"issue":"10","key":"2026022411390278000_bib24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000529191","article-title":"Cytogenetic abnormalities in multiple myeloma: incidence, prognostic significance, and geographic heterogeneity in Indian and Western populations","volume":"162","author":"Kadam Amare","year":"2022","journal-title":"Cytogenet Genome Res"},{"issue":"4","key":"2026022411390278000_bib25","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"issue":"27","key":"2026022411390278000_bib26","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","article-title":"Prognostic significance of copy-number alterations in multiple myeloma","volume":"27","author":"Avet-Loiseau","year":"20 2009","journal-title":"J Clin Oncol"},{"issue":"15","key":"2026022411390278000_bib27","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/onc.2016.368","article-title":"Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease","volume":"36","author":"van Andel","year":"2017","journal-title":"Oncogene"},{"key":"2026022411390278000_bib28","doi-asserted-by":"crossref","first-page":"215791","DOI":"10.1016\/j.canlet.2022.215791","article-title":"Targeting the oncogenic transcription factor c-Maf for the treatment of multiple myeloma","volume":"543","author":"Jiang","year":"2022","journal-title":"Cancer Lett"},{"issue":"3","key":"2026022411390278000_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/epigenomes2030016","article-title":"Targeting EZH2 in multiple myeloma-multifaceted anti-tumor activity","volume":"2","author":"Alzrigat","year":"2018","journal-title":"Epigenomes"},{"issue":"1","key":"2026022411390278000_bib30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13148-022-01314-7","article-title":"Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma","volume":"14","author":"Zhang","year":"2022","journal-title":"Clin Epigenetics"},{"issue":"9","key":"2026022411390278000_bib31","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1182\/blood-2003-07-2254","article-title":"Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells","volume":"103","author":"Jundt","year":"2004","journal-title":"Blood"},{"key":"2026022411390278000_bib32","first-page":"4112016","article-title":"Evidence for ABL amplification in multiple myeloma and therapeutic implications","volume":"2022","author":"Huang","year":"2022","journal-title":"J Oncol"},{"issue":"13","key":"2026022411390278000_bib33","doi-asserted-by":"crossref","first-page":"6991","DOI":"10.3390\/ijms25136991","article-title":"The interplay between the DNA damage response (DDR) network and the mitogen-activated protein kinase (MAPK) signaling pathway in multiple myeloma","volume":"25","author":"Malamos","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2026022411390278000_bib34","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol"},{"issue":"1","key":"2026022411390278000_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ijlh.12882","article-title":"Recent advances in cytogenetic characterization of multiple myeloma","volume":"41","author":"Saxe","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"5","key":"2026022411390278000_bib36","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood-2014-07-584268","article-title":"Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations","volume":"125","author":"Pawlyn","year":"2015","journal-title":"Blood"},{"key":"2026022411390278000_bib37","doi-asserted-by":"crossref","first-page":"938550","DOI":"10.3389\/fonc.2022.938550","article-title":"Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"issue":"23","key":"2026022411390278000_bib38","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.3390\/cancers15235690","article-title":"Cytogenetic profile in monoclonal gammopathy of undetermined significance, smoldering and symptomatic multiple myeloma: a study of 1087 patients with highly purified plasma cells","volume":"15","author":"Tang","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2026022411390278000_bib39","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.2022017863","article-title":"Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor","volume":"141","author":"Schavgoulidze","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2026022411390278000_bib40","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J"},{"issue":"2","key":"2026022411390278000_bib41","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/cells10020336","article-title":"Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications","volume":"10","author":"Cardona-Benavides","year":"2021","journal-title":"Cells"},{"issue":"1","key":"2026022411390278000_bib42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41408-025-01286-w","article-title":"Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group","volume":"15","author":"Lu","year":"2025","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026022411390278000_bib43","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ejh.14352","article-title":"Chromosome 1 alterations in multiple myeloma: considerations for precision therapy","volume":"114","author":"McAuley","year":"2025","journal-title":"Eur J Haematol"},{"issue":"2","key":"2026022411390278000_bib44","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2141.2008.07454.x","article-title":"The prognostic significance of 8p21 deletion in multiple myeloma","volume":"144","author":"Sutlu","year":"2009","journal-title":"Br J Haematol"},{"issue":"9","key":"2026022411390278000_bib45","doi-asserted-by":"crossref","first-page":"e0138248","DOI":"10.1371\/journal.pone.0138248","article-title":"Deletion of chromosomal region 8p21 confers resistance to bortezomib and is associated with upregulated decoy TRAIL receptor expression in patients with multiple myeloma","volume":"10","author":"Duru","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"2026022411390278000_bib46","doi-asserted-by":"crossref","first-page":"9434","DOI":"10.18632\/oncotarget.3319","article-title":"Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"2026022411390278000_bib47","unstructured":"Chinese Clinical Trial Registry. Prognosis in Multiple Myeloma by Copy Number Variants Identified by Shallow Whole-Genome Sequencing: a Multicenter Research. https:\/\/www.chictr.org.cn\/showproj.html?proj=210335."},{"issue":"19","key":"2026022411390278000_bib48","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.3390\/cancers15194687","article-title":"Optical genome mapping reveals the complex genetic landscape of myeloma","volume":"15","author":"Gigu\u00e8re","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1312\/2503896\/blooda_adv-2025-018133-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1312\/2503896\/blooda_adv-2025-018133-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:39:12Z","timestamp":1771951152000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/4\/1312\/557306\/Genome-wide-copy-number-profiling-enhances-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018133","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,24]]},"published":{"date-parts":[[2026,2,13]]}}}